Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 85 Cash-to-Debt is 6.38 as of Dec. 2025, which is 48% below its 10-year median of 12.31. GuruFocus rates DIUXF with a GF Score™ of 85/100 and a GF Value™ of $2.71. The stock has 1 warning sign investors should review. Among 666 Healthcare Providers & Services companies, Diaceutics ranks better than 77.18% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Diaceutics's cash to debt ratio for the quarter that ended in Dec. 2025 was 6.38.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Diaceuticscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Diaceutics's Cash-to-Debt or its related term are showing as below:
DIUXF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.55 Med: 12.31 Max: 214.03
Current: 6.38
During the past 10 years, Diaceutics's highest Cash to Debt Ratio was 214.03. The lowest was 0.55. And the median was 12.31.
DIUXF's Cash-to-Debt is ranked better than 77.18% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 0.77
vs DIUXF: 6.38
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Diaceutics Cash-to-Debt Related Terms
Diaceutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Diaceutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, Diaceutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Diaceutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (DIUXF) has a Cash-to-Debt of 6.38 as of Dec. 2025. This is 48% below median its historical median of 12.31. Over the past decade, Diaceutics' Cash-to-Debt has ranged from 0.55 to 214.03. According to the industry distribution chart, Diaceutics ranks #152 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 22.8%.
Is Diaceutics' Cash-to-Debt too high?
Diaceutics' current Cash-to-Debt of 6.38 is 48% below median its 10-year median of 12.31. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 214.03. The Healthcare Providers & Services industry median Cash-to-Debt is 0.77. Diaceutics' value of 6.38 is 728.6% above this industry median. Based on the distribution chart, Diaceutics ranks #152 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diaceutics has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #152 out of 666 companies for Cash-to-Debt. This places Diaceutics in the top 23% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.77. Diaceutics' value of 6.38 is 728.6% above this benchmark. Historically, Diaceutics' own Cash-to-Debt has ranged from 0.55 to 214.03 over the past decade. While the company's 10-year median is 12.31 vs. the industry median of 0.77, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.77, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Cash-to-Debt of 6.38 is 728.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Cash-to-Debt is 6.38, which is 48% below median its own 10-year median of 12.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Diaceutics (DIUXF) has a current Cash-to-Debt of 6.38. The stock's GF Value™ is $2.71, compared to a current price of $2.00 — trading 26.2% below its estimated fair value. The current Cash-to-Debt is 6.38, which is 48% below median its 10-year median of 12.31 and 728.6% above the Healthcare Providers & Services industry median of 0.77. Diaceutics' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Cash-to-Debt is 6.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 26.2% below its estimated GF Value™ of $2.71.
Key valuation signals for DIUXF:
Cash-to-Debt: 6.38 (48% below median its 10-year median of 12.31)
GF Value™: $2.71 vs. price of $2.00 (26.2% below fair value)
Industry Position: 728.6% above the Healthcare Providers & Services median (#152 of 666)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
85GF Score
Get the complete analysis for DIUXF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
